Ofichem has agreed to acquire Kinentia Biosciences, a US drug substance contract development and manufacturing organisation (CDMO), in a deal that will give the Dutch company an operational presence in the US. Kinentia, based in Rensselaer, New York, supports pharmaceutical and biotechnology companies with early-stage development, preclinical programmes and clinical development activities. The transaction remains […]
The post Ofichem acquires US drug substance CDMO Kinentia appeared first on Pharmafile.